Your browser doesn't support javascript.
loading
Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.
DeLeon, Thomas T; Almquist, Daniel R; Kipp, Benjamin R; Langlais, Blake T; Mangold, Aaron; Winters, Jennifer L; Kosiorek, Heidi E; Joseph, Richard W; Dronca, Roxana S; Block, Matthew S; McWilliams, Robert R; Kottschade, Lisa A; Rumilla, Kandelaria M; Voss, Jesse S; Seetharam, Mahesh; Sekulic, Aleksandar; Markovic, Svetomir N; Bryce, Alan H.
Afiliação
  • DeLeon TT; Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America.
  • Almquist DR; Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America.
  • Kipp BR; Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.
  • Langlais BT; Department of Biostatistics, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America.
  • Mangold A; Department of Dermatology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America.
  • Winters JL; Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.
  • Kosiorek HE; Department of Biostatistics, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America.
  • Joseph RW; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.
  • Dronca RS; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.
  • Block MS; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.
  • McWilliams RR; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.
  • Kottschade LA; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.
  • Rumilla KM; Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.
  • Voss JS; Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.
  • Seetharam M; Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America.
  • Sekulic A; Department of Dermatology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America.
  • Markovic SN; Mayo Clinic Cancer Center, Phoenix, Arizona, United States of America.
  • Bryce AH; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America.
PLoS One ; 15(3): e0230306, 2020.
Article em En | MEDLINE | ID: mdl-32196516
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína Supressora de Tumor p53 / Inibidor p16 de Quinase Dependente de Ciclina / Antígeno CTLA-4 / Receptor de Morte Celular Programada 1 / Imunoterapia / Melanoma Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína Supressora de Tumor p53 / Inibidor p16 de Quinase Dependente de Ciclina / Antígeno CTLA-4 / Receptor de Morte Celular Programada 1 / Imunoterapia / Melanoma Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article